A5089215502- Endometrial and Cervical Cancer Treatments
- Lung Cancer Treatments and Mutations
- Sarcoma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- PARP inhibition in cancer therapy
- Colorectal and Anal Carcinomas
- Lymphoma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Immunotherapy and Immune Responses
- Pancreatitis Pathology and Treatment
- Colorectal Cancer Treatments and Studies
- Gallbladder and Bile Duct Disorders
- Cancer Diagnosis and Treatment
- RNA Research and Splicing
- Reproductive System and Pregnancy
- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Diet and metabolism studies
- RNA modifications and cancer
- Multiple and Secondary Primary Cancers
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
Vall d'Hebron Institute of Oncology
2019-2025
Vall d'Hebron Hospital Universitari
2017-2025
Institut Gustave Roussy
2022-2024
Inserm
2023-2024
Valencian Infertility Institute
2024
Hospital Arnau de Vilanova
2016
Universitätsklinikum Tübingen
2009
Stony Brook University
2006
Hospital Universitari i Politècnic La Fe
2005
Hospital Clínico Universitario de Valencia
1997-1999
Background Patients with metastatic, recurrent, or persistent cervical cancer not amenable to local control and/or distant metastases have a very poor prognosis, only being candidates for palliative-systemic therapy. First line standard treatment in this scenario is based on cisplatin/paclitaxel plus bevacizumab (GOG 240 regimen) short median overall survival (16.8 months) and progression-free (8.2 months). Primary objective To determine whether the addition of atezolizumab...
Small intestinal bacterial overgrowth (SIBO) arises from dysbiosis in the small intestine, manifesting with abdominal symptoms. This study aims to assess efficacy of combined antibiotic therapy, herbal supplements, probiotics, and dietary modifications SIBO management. A total 179 SIBO-diagnosed patients underwent clinical evaluation breath testing. Patients were categorized into hydrogen (H2-SIBO) methane (CH4-SIBO) groups. The control group received standard therapy a low-FODMAP diet,...
Background: Small intestinal bacterial overgrowth (SIBO) is a dysbiosis marked by an excessive proliferation of bacteria in the small intestine, resulting abdominal symptoms that significantly affect patients’ quality life. Objectives: This study aims to evaluate impact comprehensive therapeutic approach improving life patients with SIBO. Methods: For this purpose, standardized questionnaires were used at baseline, 30 days and 90 days, including IBS-QOL (Irritable Bowel Syndrome Quality Life...
<h3>Background</h3> Currently, women diagnosed with high-risk locally advanced cervical cancer are at high risk of recurrence after treatment concurrent chemoradiation and represent a population unmet need. <h3>Primary Objective</h3> The primary objective is to evaluate the progression-free survival patients who have achieved partial or complete response receiving dostarlimab as maintenance therapy. <h3>Study Hypothesis</h3> study aims demonstrate that use dostarlimab, therapy, would...
Background Patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) can derive great benefit from immune checkpoint inhibitors (ICI). However not all responses and predictors of primary resistance are lacking. Methods We compared the tumor microenvironment MMRd EC ICI-responders (Rs) ICI non-responders (NRs), using spatial multiplexed profiling unsupervised hierarchical clustering analysis. Results Overall, NRs exhibited drastically lower CD8 + , absent terminally...
During the past decade, considerable strides have been made in understanding and treatment of gynecologic cancers. The advent PARP inhibitors, antiangiogenic therapies, immunotherapy combinations, targeted agents altered standard care ovarian, endometrial, cervical However, continued advancement cancers is critical. Fortunately, exciting work defining new therapeutic targets novel strategies on horizon. Here, we discuss emerging treatments for cancers, including cervical, rare We highlight...
Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain TGFβ receptor II (a "trap") fused to human IgG1 mAb blocking programmed death-ligand 1 (PD-L1), was evaluated as treatment in patients with locally advanced or persistent, recurrent, metastatic (P/R/M) cervical cancer.
Abstract Purpose: This study investigates changes in CD8+ cells, CD8+/Foxp3 ratio, HLA I expression, and immune coregulator density at diagnosis upon neoadjuvant chemotherapy (NACT), correlating with clinical outcomes. Experimental Design: Multiplexed profiling cell clustering analysis were performed on paired matched ovarian cancer samples to characterize the tumor microenvironment (iTME) under NACT patients enrolled CHIVA trial (NCT01583322). Results: Several (IC) subsets coregulators...
Serum increases of aminotransferases, especially alanine aminotransferase (ALT), were suggestive microlithiasis in idiopathic acute pancreatitis, particularly when assessed early after the onset abdominal pain.It has been shown that biochemical laboratory values only are useful parameters distinguishing gallstone from nongallstone pancreatitis. We diagnostic usefulness (ALT) and aspartate (AST) for identification occult pancreatitis.Ninety-one patients with pancreatitis who underwent...
Cervical cancer is the fourth most common in women worldwide, with a global incidence of 604,127 and an annual death rate 341,831 2020. Patients recurrent, persistent, or metastatic disease not amenable to curative therapy represent patient population dismal prognosis. Until recently, standard care for these patients was based on platinum doublet chemotherapy without bevacizumab. However, significant advances treatment landscape this have recently been achieved incorporation, among others,...
<p>Figure S1. Change from baseline in sum of diameters all target lesions per RECIST v1.1 for (A) Cohort 1A and (B) 1B. CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial SD, stable disease.</p>
<p>Figure S2. Change from baseline in sum of diameters all target lesions per RECIST v1.1 for Cohort 2. CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial SD, stable disease.</p>
<p>Figure S2. Change from baseline in sum of diameters all target lesions per RECIST v1.1 for Cohort 2. CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial SD, stable disease.</p>
<div>AbstractPurpose:<p>Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain TGFβ receptor II (a “trap”) fused to human IgG1 mAb blocking programmed death-ligand 1 (PD-L1), was evaluated as treatment in patients with locally advanced or persistent, recurrent, metastatic (P/R/M) cervical cancer.</p>Patients and Methods:<p>In this multicenter, open-label, phase Ib trial (NCT04551950), P/R/M cancer received bintrafusp alfa...
<div>AbstractPurpose:<p>Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain TGFβ receptor II (a “trap”) fused to human IgG1 mAb blocking programmed death-ligand 1 (PD-L1), was evaluated as treatment in patients with locally advanced or persistent, recurrent, metastatic (P/R/M) cervical cancer.</p>Patients and Methods:<p>In this multicenter, open-label, phase Ib trial (NCT04551950), P/R/M cancer received bintrafusp alfa...